Business

IGBA, Celltrion, Others Mark Biosimilar Advances

January 17, 2021

Tony Hagen

Article

The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14, 2021

Deana Ferreri, PhD

Article

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

Study: Machine Learning Could Optimize Biosimilar Therapy

January 12, 2021

Deana Ferreri, PhD

Article

Authors of a new study conclude that artificial intelligence could improve the selection of biosimilars for therapy.

Data From HERITAGE Confirm PK Biosimilarity for Ogivri

January 9, 2021

Tony Hagen

Article

Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4, 2021

Tony Hagen

Article

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Alvotech Breaks Ground for Biosimilar Development Facility

January 3, 2021

Tony Hagen

Article

An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.

Innovent Biologics Gains NMPA Approval for Additional Sulinno Indications

December 31, 2020

Tony Hagen

Article

China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.

A Review of the Most-Read Biosimilar Stories of 2020: Part 2

December 27, 2020

Tony Hagen

Article

In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.

Pandemic Delays FDA Decision on Biocon's Bevacizumab Application

December 26, 2020

Tony Hagen

Article

MYL-14020 could have been the fourth US biosimilar approved by the end of 2020, but the FDA hasn't been able to complete a necessary foreign inspection, owing to the pandemic.

x